iRhythm Technologies, Inc. (NASDAQ:IRTC – Get Free Report) has received an average rating of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $131.33.
Several research analysts recently commented on the stock. Oppenheimer raised their price target on shares of iRhythm Technologies from $125.00 to $165.00 in a research note on Friday, August 4th. Citigroup decreased their price target on shares of iRhythm Technologies from $115.00 to $100.00 in a research note on Monday, October 2nd. StockNews.com cut iRhythm Technologies from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Morgan Stanley decreased their target price on iRhythm Technologies from $149.00 to $135.00 and set an “overweight” rating for the company in a research report on Wednesday, October 11th. Finally, Needham & Company LLC dropped their price target on iRhythm Technologies from $140.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd.
Institutional Investors Weigh In On iRhythm Technologies
iRhythm Technologies Stock Performance
IRTC stock opened at $81.60 on Thursday. iRhythm Technologies has a twelve month low of $70.24 and a twelve month high of $140.23. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -23.58 and a beta of 1.32. The business’s fifty day simple moving average is $84.96 and its two-hundred day simple moving average is $100.98. The company has a quick ratio of 2.16, a current ratio of 2.29 and a debt-to-equity ratio of 0.16.
iRhythm Technologies Company Profile
iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.
- Five stocks we like better than iRhythm Technologies
- Stock Sentiment Analysis: How it Works
- 3 value stocks you shouldn’t let go of this quarter
- What is the S&P 500 and How It is Distinct from Other Indexes
- 5 must-have next-gen technologies that institutions are buying
- How to Read Stock Charts for Beginners
- 3 intriguing late-week earnings plays for short-term traders
Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.